2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2687

Clinicopathologic Associations in a Large International Cohort of Patients with Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2636

Cluster Analysis for Classification of Japanese Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Subgroup Analysis of Nationwide Cohort Studies

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2070

Co-morbidities in Patients with OA and RA: Results from a Large US Rheumatic Disease Registry

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Abstract Number: 2664

Color Doppler Ultrasound for the Diagnosis of Giant Cell Arteritis in Montreal: A Canadian Single Center Experience

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2126

Combined Detection of Cytokines and Biomarkers Improve the Diagnostic Performance of Bacteria Infection in Rheumatoid Arthritis

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2287

Combined First-Trimester Serum BAFF and sFlt-1 Levels as an Early Biomarker of Spontaneous Abortion

Reproductive Issues In Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1963

Combining Clinical and Candidate Gene Data into a Risk Score for Azathioprine-Associated Leukopenia in Routine Clinical Practice

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2378

Comparative Analysis of Clinical, Laboratory and Therapeutic Strategies Among Blacks with Rhupus, SLE and RA

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: L01

Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study

Late-Breaking Abstracts ePoster

9:00AM-11:00AM: Abstract Number: 2643

Comparative Study of Renal Transplantation Due to Rapidly Progressive Glomerulonephritis (RPGN): Study of 42 Patients from a Single Tertiary Centre

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2253

Comparing Patient and Provider Perspectives on Long Term Biologic Use and Tapering in Stable, Well-Controlled Rheumatoid Arthritis

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2483

Comparison Between Composite Activity Indices to Assess Clinical Response to Biological Therapy in Patients with Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2302

Comparison Between Fibromyalgia and Neuropathic Pain in Patients with Established Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2624

Comparison Between Long-Term and Conventional Rituximab-Maintenance Treatments: Results of a Placebo-Controlled Randomized Trial

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2652

Comparison Between Transmural and Isolated Periadventitial And/or Adventitial Inflammation at Temporal Artery Biopsy: A Single Center Cohort of Biopsy-Positive GCA with Long Term Follow-up

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.